ICAM1 and cancer: The anti-leukemic action of NK cells would also be strengthened by the ability of SUMOylation inhibition to induce the expression of NK-activating ligands at the surface of cancer cells, as we demonstrated for ICAM-1 on AML cells (15) and as it was shown for PVR on Multiple Myeloma cells (46).